Search

Your search keyword '"Giralt, Sergio"' showing total 4,594 results
Start Over Author "Giralt, Sergio"

Refine your results

more »

more »

more »

more »

more »
4,594 results on '"Giralt, Sergio"'

51. 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes

Author

Foran, James, primary, Gyurkocza, Boglarka, additional, Nath, Rajneesh, additional, Choe, Hannah, additional, Litzow, Mark R., additional, Abboud, Camille, additional, Koshy, Nebu, additional, Stiff, Patrick J., additional, Tomlinson, Benjamin, additional, Abhyankar, Sunil H., additional, Abedin, Sameem, additional, Chen, George L, additional, Al-Kadhimi, Zaid, additional, Kebriaei, Partow, additional, Sabloff, Mitchell, additional, Orozco, Johnnie J., additional, Jamieson, Katarzyna, additional, Magalhaes-Silverman, Margarida, additional, van Besien, Koen, additional, Schuster, Michael W, additional, Law, Arjun D., additional, Mayer, Sebastian, additional, Lazarus, Hillard M, additional, Spross, Jennifer, additional, Li, Kate L, additional, Nagl, Norman G, additional, Brodin, Patrik, additional, Vusirikala, Madhuri, additional, Nahar, Akash, additional, Sandmaier, Prof. Brenda M., additional, Pagel, John M., additional, Giralt, Sergio A., additional, Desai, Avinash, additional, and Seropian, Stuart, additional

Published
2024
Full Text
View/download PDF

52. Early CD4 and B Cell Immune Reconstitution As Predictors of Outcomes in T Cell Depleted Allogeneic Hematopoietic Cell Transplantation

Author

Lucas, Alexandre G. Troullioud, primary, Scordo, Michael, additional, Lakkaraja, Madhavi, additional, Cho, Christina, additional, Jakubowski, Ann A., additional, Papadopoulos, Esperanza B., additional, Tamari, Roni, additional, Curran, Kevin J., additional, O'Reilly, Richard J., additional, Scaradavou, Andromachi, additional, Gyurkocza, Boglarka, additional, Giralt, Sergio A., additional, Perales, Miguel-Angel, additional, and Boelens, Jaap Jan, additional

Published
2024
Full Text
View/download PDF

53. Discovery Proteomics for Analytes to Predict Outcomes after Hematopoietic Stem Cell Transplantation: A Real World Experience from BMT-CTN-1202

Author

Lakkaraja, Madhavi, primary, Mauguen, Audrey, additional, McAvoy, Devin, additional, Hosszu, Kinga, additional, Singh, Katina H, additional, Vidal, Esther H, additional, Stewart, Dr. Valerie, additional, Schmidt, Gabrielle, additional, Levine, John E, additional, Perales, Miguel-Angel, additional, Giralt, Sergio A., additional, Baker, K. Scott, additional, and Boelens, Jaap-Jan, additional

Published
2024
Full Text
View/download PDF

54. Patterns of CMV Infection after Letermovir Withdrawal in Recipients of Post-Transplant Cyclophosphamide Based Transplant

Author

Lin, Andrew, primary, Brown, Samantha, additional, Chinapen, Ms. Stephanie, additional, Lee, Yeon Joo, additional, Seo, Susan K., additional, Ponce, Doris M., additional, Shahid, Zainab, additional, Giralt, Sergio A., additional, Papanicolaou, Genovefa A, additional, Perales, Miguel-Angel, additional, and Shaffer, Brian C., additional

Published
2024
Full Text
View/download PDF

55. Use of a Tissue-Targeting Recombinant Human Interleukin-22 Fusion Molecule (F-652) for the Treatment of Advanced Refractory Lower GI Acute Gvhd

Author

Satta, Dr. Toshihisa, primary, Papadopoulos, Esperanza B., additional, Gyurkocza, Boglarka, additional, Susman, Pamela, additional, Singh, Amandeep, additional, Calafiore, Marco, additional, Giralt, Sergio A., additional, Perales, Miguel-Angel, additional, Li, Simon, additional, Chen, Jianmin, additional, Peled, Jonathan U., additional, van den Brink, Marcel R.M., additional, Hanash, Alan M., additional, and Ponce, Doris M., additional

Published
2024
Full Text
View/download PDF

56. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Author

Smith, Melody, Dai, Anqi, Ghilardi, Guido, Amelsberg, Kimberly V., Devlin, Sean M., Pajarillo, Raymone, Slingerland, John B., Beghi, Silvia, Herrera, Pamela S., Giardina, Paul, Clurman, Annelie, Dwomoh, Emmanuel, Armijo, Gabriel, Gomes, Antonio L. C., Littmann, Eric R., Schluter, Jonas, Fontana, Emily, Taur, Ying, Park, Jae H., Palomba, Maria Lia, Halton, Elizabeth, Ruiz, Josel, Jain, Tania, Pennisi, Martina, Afuye, Aishat Olaide, Perales, Miguel-Angel, Freyer, Craig W., Garfall, Alfred, Gier, Shannon, Nasta, Sunita, Landsburg, Daniel, Gerson, James, Svoboda, Jakub, Cross, Justin, Chong, Elise A., Giralt, Sergio, Gill, Saar I., Riviere, Isabelle, Porter, David L., Schuster, Stephen J., Sadelain, Michel, Frey, Noelle, Brentjens, Renier J., June, Carl H., Pamer, Eric G., Peled, Jonathan U., Facciabene, Andrea, van den Brink, Marcel R. M., and Ruella, Marco

Published
2022
Full Text
View/download PDF

58. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

Author

Bolaños-Meade, Javier, Reshef, Ran, Fraser, Raphael, Fei, Mingwei, Abhyankar, Sunil, Al-Kadhimi, Zaid, Alousi, Amin M, Antin, Joseph H, Arai, Sally, Bickett, Kate, Chen, Yi-Bin, Damon, Lloyd E, Efebera, Yvonne A, Geller, Nancy L, Giralt, Sergio A, Hari, Parameswaran, Holtan, Shernan G, Horowitz, Mary M, Jacobsohn, David A, Jones, Richard J, Liesveld, Jane L, Logan, Brent R, MacMillan, Margaret L, Mielcarek, Marco, Noel, Pierre, Pidala, Joseph, Porter, David L, Pusic, Iskra, Sobecks, Ronald, Solomon, Scott R, Weisdorf, Daniel J, Wu, Juan, Pasquini, Marcelo C, and Koreth, John

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Trials and Supportive Activities, Hematology, Transplantation, Cancer, Rare Diseases, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Bortezomib, Cyclophosphamide, Drug Interactions, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Male, Maraviroc, Methotrexate, Middle Aged, Mycophenolic Acid, Tacrolimus, Transplantation Conditioning, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

BackgroundPrevention of graft-versus-host disease (GvHD) without malignant relapse is the overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate regimens using either maraviroc, bortezomib, or post-transplantation cyclophosphamide for GvHD prophylaxis compared with controls receiving the combination of tacrolimus and methotrexate using a novel composite primary endpoint to identify the most promising intervention to be further tested in a phase 3 trial.MethodsIn this prospective multicentre phase 2 trial, adult patients aged 18-75 years who received reduced-intensity conditioning HCT were randomly assigned (1:1:1) by random block sizes to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide (cyclophosphamide 50 mg/kg on days 3 and 4, followed by tacrolimus starting on day 5 and mycophenolate mofetil starting on day 5 at 15 mg/kg three times daily not to exceed 1 g from day 5 to day 35); tacrolimus, methotrexate, and bortezomib (bortezomib 1·3 mg/m2 intravenously on days 1, 4, and 7 after HCT); or tacrolimus, methotrexate, and maraviroc (maraviroc 300 mg orally twice daily from day -3 to day 30 after HCT). Methotrexate was administered as a 15 mg/m2 intravenous bolus on day 1 and 10 mg/m2 intravenous bolus on days 3, 6, and 11 after HCT; tacrolimus was given intravenously at a dose of 0·05 mg/kg twice daily (or oral equivalent) starting on day -3 (except the post-transplantation cyclophosphamide, as indicated), with a target level of 5-15 ng/mL. Tacrolimus was continued at least until day 90 and was tapered off by day 180. Each study group was compared separately to a contemporary non-randomised prospective cohort of patients (control group) who fulfilled the same eligibility criteria as the trial, but who were treated with tacrolimus and methotrexate at centres not participating in the trial. The primary endpoint (GvHD-free, relapse-free survival [GRFS]) was defined as the time from HCT to onset of grade 3-4 acute GvHD, chronic GvHD requiring systemic immunosuppression, disease relapse, or death. The study was analysed by modified intention to treat. The study is closed to accrual and this is the planned analysis. This trial is registered with ClinicalTrials.gov, number NCT02208037.FindingsBetween Nov 17, 2014, and May 18, 2016, 273 patients from 31 US centres were randomly assigned to the three study arms: 89 to tacrolimus, methotrexate, and bortezomib; 92 to tacrolimus, methotrexate, and maraviroc; 92 to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; and six were excluded. Between Aug 1, 2014, and Sept 14, 2016, 224 controls received tacrolimus and methotrexate. Controls were generally well matched except for more frequent comorbidities than the intervention groups and a different distribution of types of conditioning regimens used. Compared with controls, the hazard ratio for GRFS was 0·72 (90% CI 0·54-0·94; p=0·044) for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide, 0·98 (0·76-1·27; p=0·92) for tacrolimus, methotrexate, and bortezomib, and 1·10 (0·86-1·41; p=0·49) for tacrolimus, methotrexate, and maraviroc. 238 patients experienced grade 3 or 4 toxicities: 12 (13%) had grade 3 and 67 (73%) grade 4 events with tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; ten (11%) had grade 3 and 68 (76%) had grade 4 events with tacrolimus, methotrexate, and bortezomib; and 18 (20%) had grade 3 and 63 (68%) had grade 4 events with tacrolimus, methotrexate, and maraviroc. The most common toxicities were haematological (77 [84%] for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; 73 [82%] for tacrolimus, methotrexate, and bortezomib; and 78 [85%] for tacrolimus, methotrexate, and maraviroc) and cardiac (43 [47%], 44 [49%], and 43 [47%], respectively).InterpretationTacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide was the most promising intervention, yielding the best GRFS; this regimen is thus being prospectively compared with tacrolimus and methotrexate in a phase 3 randomised trial.FundingUS National Health, Lung, and Blood Institute; National Cancer Institute; National Institute of Allergy and Infectious Disease; and Millennium Pharmaceuticals.

Published
2019

59. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

Author

Stadtmauer, Edward A, Pasquini, Marcelo C, Blackwell, Beth, Hari, Parameswaran, Bashey, Asad, Devine, Steven, Efebera, Yvonne, Ganguly, Siddharta, Gasparetto, Cristina, Geller, Nancy, Horowitz, Mary M, Koreth, John, Knust, Kristin, Landau, Heather, Brunstein, Claudio, McCarthy, Philip, Nelson, Courtney, Qazilbash, Muzaffar H, Shah, Nina, Vesole, David H, Vij, Ravi, Vogl, Dan T, Giralt, Sergio, Somlo, George, and Krishnan, Amrita

Subjects
Cancer, Clinical Trials and Supportive Activities, Hematology, Clinical Research, Rare Diseases, Transplantation, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Consolidation Chemotherapy, Dexamethasone, Disease Progression, Female, Hematopoietic Stem Cell Transplantation, Humans, Lenalidomide, Maintenance Chemotherapy, Male, Melphalan, Middle Aged, Multiple Myeloma, Myeloablative Agonists, Progression-Free Survival, Prospective Studies, Remission Induction, Reoperation, Time Factors, Transplantation, Autologous, United States, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeSingle-cycle melphalan 200 mg/m2 and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free survival (PFS) and overall survival (OS) for transplantation-eligible patients with multiple myeloma (MM). We designed a prospective, randomized, phase III study to test additional interventions to improve PFS by comparing AHCT, tandem AHCT (AHCT/AHCT), and AHCT and four subsequent cycles of len, bortezomib, and dexamethasone (RVD; AHCT + RVD), all followed by len until disease progression.Patients and methodsPatients with symptomatic MM within 12 months from starting therapy and without progression who were age 70 years or younger were randomly assigned to AHCT/AHCT + len (n = 247), AHCT + RVD + len (n = 254), or AHCT + len (n = 257). The primary end point was 38-month PFS.ResultsThe study population had a median age of 56 years (range, 20 to 70 years); 24% of patients had high-risk MM, 73% had a triple-drug regimen as initial therapy, and 18% were in complete response at enrollment. The 38-month PFS rate was 58.5% (95% CI, 51.7% to 64.6%) for AHCT/AHCT + len, 57.8% (95% CI, 51.4% to 63.7%) for AHCT + RVD + len, and 53.9% (95% CI, 47.4% to 60%) for AHCT + len. For AHCT/AHCT + len, AHCT + RVD + len, and AHCT + len, the OS rates were 81.8% (95% CI, 76.2% to 86.2%), 85.4% (95% CI, 80.4% to 89.3%), and 83.7% (95% CI, 78.4% to 87.8%), respectively, and the complete response rates at 1 year were 50.5% (n = 192), 58.4% (n = 209), and 47.1% (n = 208), respectively. Toxicity profiles and development of second primary malignancies were similar across treatment arms.ConclusionSecond AHCT or RVD consolidation as post-AHCT interventions for the up-front treatment of transplantation-eligible patients with MM did not improve PFS or OS. Single AHCT and len should remain as the standard approach for this population.

Published
2019

60. Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant

Author

Miltiadous, Oriana, Waters, Nicholas R., Andrlová, Hana, Dai, Anqi, Nguyen, Chi L., Burgos da Silva, Marina, Lindner, Sarah, Slingerland, John, Giardina, Paul, Clurman, Annelie, Armijo, Gabriel K., Gomes, Antonio L.C., Lakkaraja, Madhavi, Maslak, Peter, Scordo, Michael, Shouval, Roni, Staffas, Anna, O'Reilly, Richard, Taur, Ying, Prockop, Susan, Boelens, Jaap Jan, Giralt, Sergio, Perales, Miguel-Angel, Devlin, Sean M., Peled, Jonathan U., Markey, Kate A., and van den Brink, Marcel R.M.

Published
2022
Full Text
View/download PDF

62. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT

Author

Shouval, Roni, Fein, Joshua A., Cho, Christina, Avecilla, Scott T., Ruiz, Josel, Tomas, Ana Alarcon, Sanchez-Escamilla, Miriam, Flores, Nerea Castillo, Yáñez, Lucrecia, Barker, Juliet N., Dahi, Parastoo, Giralt, Sergio A., Geyer, Alexander I., Gyurkocza, Boglarka, Jakubowski, Ann A., Lin, Richard J., O'Reilly, Richard J., Papadopoulos, Esperanza B., Politikos, Ioannis, Ponce, Doris M., Sauter, Craig S., Scordo, Michael, Shaffer, Brian, Shah, Gunjan L., Sullivan, James P., Tamari, Roni, van den Brink, Marcel R.M., Young, James W., Nagler, Arnon, Devlin, Sean, Shimoni, Avichai, and Perales, Miguel-Angel

Published
2022
Full Text
View/download PDF

63. Antithymocyte globulin exposure in CD34+ T-cell–depleted allogeneic hematopoietic cell transplantation

Author

Lakkaraja, Madhavi, Scordo, Michael, Mauguen, Audrey, Cho, Christina, Devlin, Sean, Ruiz, Josel D., Klein, Elizabeth, Avecilla, Scott T., Boulad, Farid, Cancio, Maria I., Curran, Kevin J., Jakubowski, Ann A., Kernan, Nancy A., Kung, Andrew L., O'Reilly, Richard J., Papadopoulos, Esperanza B., Prockop, Susan, van Roessel, Ichelle, Scaradavou, Andromachi, Shaffer, Brian C., Shah, Gunjan, Spitzer, Barbara, Tamari, Roni, Giralt, Sergio A., Perales, Miguel-Angel, and Boelens, Jaap Jan

Published
2022
Full Text
View/download PDF

65. Interventions and outcomes of patients with multiple myeloma receiving salvage treatment after BCMA-directed CAR T therapy

Author

Van Oekelen, Oliver, Nath, Karthik, Mouhieddine, Tarek H., Farzana, Tasmin, Aleman, Adolfo, Melnekoff, David T., Ghodke-Puranik, Yogita, Shah, Gunjan L., Lesokhin, Alexander, Giralt, Sergio, Thibaud, Santiago, Rossi, Adriana, Rodriguez, Cesar, Sanchez, Larysa, Richter, Joshua, Richard, Shambavi, Cho, Hearn J., Chari, Ajai, Usmani, Saad, Jagannath, Sundar, Shah, Urvi A., Mailankody, Sham, and Parekh, Samir

Published
2022
Full Text
View/download PDF

66. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy

Author

Infante, Maria-Stefania, Nemirovsky, David, Devlin, Sean, DeWolf, Susan, Tamari, Roni, Dahi, Parastoo B., Lee, Yeon Joo, Chung, David J., Politikos, Ioannis, Barker, Juliet, Giralt, Sergio A., Babady, N. Esther, Ramanathan, Lakshmi, Papanicolaou, Genovefa A., Seo, Susan, Kamboj, Mini, Perales, Miguel-Angel, and Shah, Gunjan L.

Published
2024
Full Text
View/download PDF

67. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation

Author

Tamari, Roni, Oran, Betul, Hilden, Patrick, Maloy, Molly, Kongtim, Piyanuch, Papadopoulos, Esperanza B, Rondon, Gabriela, Jakubowski, Ann A, Andersson, Borje S, Devlin, Sean M, Ahmed, Sairah, Popat, Uday R, Ponce, Doris, Chen, Julianne, Sauter, Craig, Young, James W, de Lima, Marcos, Perales, Miguel-Angel, O'Reilly, Richard J, Giralt, Sergio A, Champlin, Richard E, and Castro-Malaspina, Hugo

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Rare Diseases, Clinical Research, Transplantation, Stem Cell Research - Nonembryonic - Human, Orphan Drug, Stem Cell Research, Regenerative Medicine, Adult, Aged, Allografts, Antigens, CD34, Chromosome Aberrations, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Lymphocyte Depletion, Male, Middle Aged, Myelodysplastic Syndromes, Recurrence, Risk Assessment, Survival Analysis, Transplantation, Homologous, Treatment Outcome, Myelodysplastic syndrome, Allogeneic transplantation, T cell depletion, Unmodified, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

In this study, we compared transplantation outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with advanced myelodysplastic syndrome (MDS) who received a CD34+ cell-selected and those who received an unmodified allograft. This analysis initially included 181 patients, 60 who received a CD34+ cell-selected transplant and 121 who received an unmodified transplant. Owing to significant differences in disease characteristics, the analysis was limited to patients with

Published
2018

68. Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma

Author

Shah, Nina, Shi, Qiuling, Giralt, Sergio, Williams, Loretta, Bashir, Qaiser, Qazilbash, Muzaffar, Champlin, Richard E, Cleeland, Charles S, and Wang, Xin Shelley

Subjects
Health Services and Systems, Health Sciences, Stem Cell Research, Transplantation, Cancer, Clinical Research, Regenerative Medicine, Hematology, Rehabilitation, Adult, Aged, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Multiple Myeloma, Patient Reported Outcome Measures, Sickness Impact Profile, Transplantation Conditioning, Patient-reported outcomes, Patient performed testing, MD Anderson Symptom Inventory, Functional status, Auto-HCT, Public Health and Health Services, Psychology, Health Policy & Services, Health sciences, Human society
Abstract

BackgroundWe aimed to determine the utility of a patient-reported outcome (PRO) as it relates to patient performed testing (PPT) for measuring functional status in multiple myeloma patients after autologous hematopoietic stem cell transplantation (auto-HCT).MethodsSymptom interference on walking (a PRO) was measured by the MD Anderson Symptom Inventory (MDASI). PPT was assessed via 6-min walk test (6MWT). Mixed effects modeling was used to examine (1) the longitudinal relationship between the MDASI score and 6MWT distance and (2) the MDASI scores between patients who did or did not complete the 6WMT. Receiver operating characteristic (ROC) curve analysis was performed to quantify the construct validity of the PRO by differentiating performance status.ResultsSeventy-nine patients were included. Mean 6MWT distance significantly correlated with MDASI-walking interference score (PRO) over the first month of auto-HCT (est = 6.09, p = 0.006). There was a significantly higher completion rate for MDASI versus 6MWT at each time point (p

Published
2018

69. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Author

Kumar, Shaji, Baizer, Lawrence, Callander, Natalie S., Giralt, Sergio A., Hillengass, Jens, Freidlin, Boris, Hoering, Antje, Richardson, Paul G., Schwartz, Elena I., Reiman, Anthony, Lentzsch, Suzanne, McCarthy, Philip L., Jagannath, Sundar, Yee, Andrew J., Little, Richard F., and Raje, Noopur S.

Published
2022
Full Text
View/download PDF

70. A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Disease Biomarkers and Delays Progression to Myeloma

Author

Shah, Urvi, primary, Cogrossi, Laura Lucia, additional, Derkach, Andriy, additional, Castro, Francesca, additional, Fei, Teng, additional, DeWolf, Susan, additional, Garces, Juan-Jose, additional, Policastro, Anna, additional, Grioni, Matteo, additional, Sisti, Sofia, additional, Blaslov, Jenna, additional, Adintori, Peter, additional, Hosszu, Kinga K., additional, McAvoy, Devin, additional, Baichoo, Mirae, additional, Cross, Justin R., additional, Anuraj, Aishwarya, additional, Pohl, Charlotte, additional, Ramos, Ruben, additional, Paredes, Jenny, additional, Gipson, Brianna, additional, Maclachlan, Kylee, additional, Gradissimo, Ana, additional, Boiocchi, Leonardo, additional, Koche, Richard, additional, Chaligne, Ronan, additional, Block, Torin, additional, Korde, Neha, additional, Tan, Carlyn Rose, additional, Hultcrantz, Malin, additional, Hassoun, Hani, additional, Shah, Gunjan, additional, Scordo, Michael, additional, Lahoud, Oscar B., additional, Chung, David J., additional, Landau, Heather J., additional, Peled, Jonathan U., additional, Clementi, Nicola, additional, Chesi, Marta, additional, Bergsagel, Peter, additional, Mailankody, Sham, additional, Pollak, Michael, additional, D'Souza, Anita, additional, Landgren, Ola, additional, Chimonas, Susan, additional, Giralt, Sergio A., additional, Usmani, Saad, additional, Iyengar, Neil M., additional, Lesokhin, Alexander, additional, Bellone, Matteo, additional, and van den Brink, Marcel R.M., additional

Published
2024
Full Text
View/download PDF

71. Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial

Author

Malek, Ehsan, primary, Kort, Jeries, additional, Metheny, Leland, additional, Fu, Pingfu, additional, Li, Gen, additional, Hari, Parameswaran, additional, Efebera, Yvonne, additional, Callander, Natalie S., additional, Qazilbash, Muzaffar H., additional, Giralt, Sergio, additional, Krishnan, Amrita, additional, Stadtmauer, Edward A., additional, and Lazarus, Hillard M, additional

Published
2024
Full Text
View/download PDF

72. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Author

Pennisi, Martina, Sanchez-Escamilla, Miriam, Flynn, Jessica R., Shouval, Roni, Alarcon Tomas, Ana, Silverberg, Mari Lynn, Batlevi, Connie, Brentjens, Renier J., Dahi, Parastoo B., Devlin, Sean M., Diamonte, Claudia, Giralt, Sergio, Halton, Elizabeth F., Jain, Tania, Maloy, Molly, Mead, Elena, Palomba, Maria Lia, Ruiz, Josel, Santomasso, Bianca, Sauter, Craig S., Scordo, Michael, Shah, Gunjan L., Park, Jae H., Yanez San Segundo, Lucrecia, and Perales, Miguel-Angel

Published
2021
Full Text
View/download PDF

73. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy

Author

Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Ayala, Ernesto, Aljurf, Mahmoud, Nishihori, Taiga, Marsh, Rebecca, Burroughs, Lauri M., Majhail, Navneet, Al-Homsi, A. Samer, Al-Kadhimi, Zaid S., Bar, Merav, Bertaina, Alice, Boelens, Jaap J., Champlin, Richard, Chaudhury, Sonali, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, El-Jawahri, Areej, Fanning, Suzanne, Fraint, Ellen, Gergis, Usama, Giralt, Sergio, Hamilton, Betty K., Hashmi, Shahrukh K., Horn, Biljana, Inamoto, Yoshihiro, Jacobsohn, David A, Jain, Tania, Johnston, Laura, Kanate, Abraham S., Kansagra, Ankit, Kassim, Adetola, Kean, Leslie S., Kitko, Carrie L., Knight-Perry, Jessica, Kurtzberg, Joanne, Liu, Hien, MacMillan, Margaret L., Mahmoudjafari, Zahra, Mielcarek, Marco, Mohty, Mohamad, Nagler, Arnon, Nemecek, Eneida, Olson, Timothy S., Oran, Betul, Perales, Miguel-Angel, Prockop, Susan E., Pulsipher, Michael A., Pusic, Iskra, Riches, Marcie L., Rodriguez, Cesar, Romee, Rizwan, Rondon, Gabriela, Saad, Ayman, Shah, Nina, Shaw, Peter J., Shenoy, Shalini, Sierra, Jorge, Talano, Julie, Verneris, Michael R., Veys, Paul, Wagner, John E., Savani, Bipin N., Hamadani, Mehdi, and Carpenter, Paul A.

Published
2021
Full Text
View/download PDF

75. MO50-4 Efficacy and safety of commercially approved BCMA-targeting CAR-T therapy in triple-class refractory multiple myeloma

Author

Nishimura, Noriko, primary, Brown, Samantha, additional, Devlin Sean, M., additional, Parastoo, Dahi, additional, Landau Heather, J., additional, Lahoud Oscar, B., additional, Michael, Scordo, additional, Shah Gunjan, L., additional, Chung David, J., additional, Hani, Hassoun, additional, Malin, Hultcrantz, additional, Neha, Korde, additional, Lesokhin Alexander, M., additional, Sham, Mailankody, additional, Shah Urvi, A., additional, Tan Carlyn, R., additional, Usmani Saad, Z., additional, and Giralt, Sergio A., additional

Published
2023
Full Text
View/download PDF

76. Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation

Author

Lahoud, Oscar B., Devlin, Sean M., Maloy, Molly A., Roeker, Lindsey E., Dahi, Parastoo B., Ponce, Doris M., Gyurkocza, Boglarka, Koehne, Guenther, Young, James W., Castro-Malaspina, Hugo R., Barker, Juliet N., Papadopoulos, Esperanza B., Jakubowski, Ann A., Zelenetz, Andrew D., Mato, Anthony R., Giralt, Sergio A., Perales, Miguel A., and Sauter, Craig S.

Published
2021
Full Text
View/download PDF

78. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial

Author

Diamond, Benjamin, Korde, Neha, Lesokhin, Alexander M, Smith, Eric L, Shah, Urvi, Mailankody, Sham, Hultcrantz, Malin, Hassoun, Hani, Lu, Sydney X, Tan, Carlyn, Rustad, Even H, Maura, Francesco, Maclachlan, Kylee, Peterson, Tim, Derkach, Andriy, Devlin, Sean, Landau, Heather J, Scordo, Michael, Chung, David J, Shah, Gunjan L, Lahoud, Oscar, Thoren, Katie, Murata, Kazunori, Ramanathan, Lakshmi, Arcila, Maria E, Ho, Caleb, Roshal, Mikhail, Dogan, Ahmet, Giralt, Sergio A, and Landgren, Ola

Published
2021
Full Text
View/download PDF

80. Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study

Author

Khan, Niloufer, Lindner, Sarah, Gomes, Antonio L.C., Devlin, Sean M., Shah, Gunjan L., Sung, Anthony D., Sauter, Craig S., Landau, Heather J., Dahi, Parastoo B., Perales, Miguel-Angel, Chung, David J., Lesokhin, Alexander M., Dai, Anqi, Clurman, Annelie, Slingerland, John B., Slingerland, Ann E., Brereton, Daniel G., Giardina, Paul A., Maloy, Molly, Armijo, Gabriel K., Rondon-Clavo, Carlos, Fontana, Emily, Bohannon, Lauren, Ramalingam, Sendhilnathan, Bush, Amy T., Lew, Meagan V., Messina, Julia A., Littmann, Eric, Taur, Ying, Jenq, Robert R., Chao, Nelson J., Giralt, Sergio, Markey, Kate A., Pamer, Eric G., van den Brink, Marcel R.M., and Peled, Jonathan U.

Published
2021
Full Text
View/download PDF

81. The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy

Author

Garcia-Recio, Marta, Wudhikarn, Kitsada, Pennisi, Martina, Alonso-Trillo, Rosalia, Flynn, Jessica, Shouval, Roni, Afuye, Aishat O., Silverberg, Mari Lynne, Batlevi, Connie W., Dahi, Parastoo, Devlin, Sean, Giralt, Sergio A., Halton, Elizabeth, Ruiz, Josel, Maloy, Molly, Mead, Elena, Palomba, M. Lia, Santomasso, Bianca, Sauter, Craig S., Scordo, Michael, Shah, Gunjan L., and Perales, Miguel-Angel

Published
2021
Full Text
View/download PDF

82. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry

Author

Shouval, Roni, Fein, Joshua A, Labopin, Myriam, Cho, Christina, Bazarbachi, Ali, Baron, Frédéric, Bug, Gesine, Ciceri, Fabio, Corbacioglu, Selim, Galimard, Jacques-Emmanuel, Giebel, Sebastian, Gilleece, Maria H, Giralt, Sergio, Jakubowski, Ann, Montoto, Silvia, O'Reilly, Richard J, Papadopoulos, Esperanza B, Peric, Zinaida, Ruggeri, Annalisa, Sanz, Jaime, Sauter, Craig S, Savani, Bipin N, Schmid, Christoph, Spyridonidis, Alexandros, Tamari, Roni, Versluis, Jurjen, Yakoub-Agha, Ibrahim, Perales, Miguel Angel, Mohty, Mohamad, and Nagler, Arnon

Published
2021
Full Text
View/download PDF

83. Nutrition perceptions, needs and practices among patients with plasma cell disorders

Author

Malik, Maria A., Sweeney, Nathan W., Jafri, Mohammad, Derkach, Andriy, Chmielewski, Cynthia, Adintori, Peter A., Mailankody, Sham, Korde, Neha, Tan, Carlyn R., Hassoun, Hani, Hultcrantz, Malin, Hillengass, Jens, McCann, Susan E., Iyengar, Neil, Usmani, Saad, Giralt, Sergio A., Landgren, Ola, van den Brink, Marcel R. M., Ahlstrom, Jennifer M., Lesokhin, Alexander M., D’Souza, Anita, Chimonas, Susan, and Shah, Urvi A.

Published
2022
Full Text
View/download PDF

84. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

Author

Firestone, Ross S., Socci, Nicholas D., Shekarkhand, Tala, Zhu, Menglei, Qin, Wei Ge, Hultcrantz, Malin, Mailankody, Sham, Tan, Carlyn Rose, Korde, Neha, Lesokhin, Alexander M., Hassoun, Hani, Shah, Urvi, Maclachlan, Kylee H., Rajeeve, Sridevi, Landau, Heather J., Scordo, Michael, Shah, Gunjan L., Lahoud, Oscar B., Giralt, Sergio, Murata, Kazunori, Usmani, Saad Z., and Chung, David J.

Abstract

•Therapy–mediated BCMA expression loss after belantamab or anti-BCMA chimeric antigen receptor T cells underlies teclistamab failure in RRMM.•Low/undetectable peripheral blood soluble BCMA reflects loss of BCMA expression by bone marrow plasma cells.

Published
2024
Full Text
View/download PDF

85. Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin

Author

Politikos, Ioannis, Devlin, Sean M., Arcila, Maria E., Barone, Jonathan C., Maloy, Molly A., Naputo, Kristine A., Ruiz, Josel D., Mazis, Christopher M., Scaradavou, Andromachi, Avecilla, Scott T., Dahi, Parastoo B., Giralt, Sergio A., Hsu, Katherine C., Jakubowski, Ann A., Papadopoulos, Esperanza B., Perales, Miguel A., Sauter, Craig S., Tamari, Roni, Ponce, Doris M., O’Reilly, Richard J., and Barker, Juliet N.

Published
2021
Full Text
View/download PDF

86. High progression-free survival after intermediate intensity double unit cord blood transplantation in adults

Author

Barker, Juliet N., Devlin, Sean M., Naputo, Kristine A., Skinner, Kelcey, Maloy, Molly A., Flynn, Lisa, Anagnostou, Theodora, Avecilla, Scott T., Scaradavou, Andromachi, Cho, Christina, Dahi, Parastoo B., Giralt, Sergio A., Gyurkocza, Boglarka, Hanash, Alan M., Hsu, Katharine, Jakubowski, Ann A., Papadopoulos, Esperanza B., Peled, Jonathan U., Perales, Miguel-Angel, Sauter, Craig S., Shah, Gunjan L., Shaffer, Brian C., Tamari, Roni, Young, James W., Roshal, Mikhail, O'Reilly, Richard J., Ponce, Doris M., and Politikos, Ioannis

Published
2020
Full Text
View/download PDF

88. Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma

Author

Gomez-Arteaga, Alexandra, Shah, Gunjan L., Baser, Raymond E., Scordo, Michael, Ruiz, Josel D., Bryant, Adam, Dahi, Parastoo B., Ghosh, Arnab, Lahoud, Oscar B., Landau, Heather J., Landgren, Ola, Shaffer, Brian C., Smith, Eric L., Koehne, Guenther, Perales, Miguel-Angel, Giralt, Sergio A., and Chung, David J.

Published
2020
Full Text
View/download PDF

89. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation

Author

Shah, Gunjan L., DeWolf, Susan, Lee, Yeon Joo, Tamari, Roni, Dahi, Parastoo B., Lavery, Jessica A., Ruiz, Josel, Devlin, Sean M., Cho, Christina, Peled, Jonathan U., Politikos, Ioannis, Scordo, Michael, Babady, N. Esther, Jain, Tania, Vardhana, Santosha, Daniyan, Anthony, Sauter, Craig S., Barker, Juliet N., Giralt, Sergio A., Goss, Cheryl, Maslak, Peter, Hohl, Tobias M., Kamboj, Mini, Ramanathan, Lakshmi, van den Brink, Marcel R.M., Papadopoulos, Esperanza, Papanicolaou, Genovefa, and Perales, Miguel-Angel

Subjects
Epidemics -- Control -- United States, Hematopoietic stem cell transplantation -- Patient outcomes, Immune response -- Observations, COVID-19 -- Control, Health care industry
Abstract

BACKGROUND. Understanding outcomes and immunologic characteristics of cellular therapy recipients with SARS-CoV-2 is critical to performing these potentially life-saving therapies in the COVID-19 era. In this study of recipients of allogeneic (Allo) and autologous (Auto) hematopoietic cell transplant and CD19-directed chimeric antigen receptor T cell (CAR T) therapy at Memorial Sloan Kettering Cancer Center, we aimed to identify clinical variables associated with COVID-19 severity and assess lymphocyte populations. METHODS. We retrospectively investigated patients diagnosed between March 15, 2020, and May 7, 2020. In a subset of patients, lymphocyte immunophenotyping, quantitative real-time PCR from nasopharyngeal swabs, and SARS-CoV-2 antibody status were available. RESULTS. We identified 77 patients with SARS-CoV-2 who were recipients of cellular therapy (Allo, 35; Auto, 37; CAR T, 5; median time from cellular therapy, 782 days; IQR, 354-1611 days). Overall survival at 30 days was 78%. Clinical variables significantly associated with the composite endpoint of nonrebreather or higher oxygen requirement and death (n events = 25 of 77) included number of comorbidities (HR 5.41, P = 0.004), infiltrates (HR 3.08, P = 0.032), and neutropenia (HR 1.15, P = 0.04). Worsening graft-versus-host disease was not identified among Allo recipients. Immune profiling revealed reductions and rapid recovery in lymphocyte populations across lymphocyte subsets. Antibody responses were seen in a subset of patients. CONCLUSION. In this series of Allo, Auto, and CAR T recipients, we report overall favorable clinical outcomes for patients with COVID-19 without active malignancy and provide preliminary insights into the lymphocyte populations that are key for the antiviral response and immune reconstitution. FUNDING. NIH grant P01 CA23766 and NIH/National Cancer Institute grant P30 CA008748., Introduction As of June 2, 2020, there were over 1.8 million confirmed cases of coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), in [...]

Published
2020
Full Text
View/download PDF

90. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor

Author

Taylor, Justin, Donoghue, Mark T.A., Ho, Caleb, Petrova-Drus, Kseniya, Al-Ahmadie, Hikmat A., Funt, Samuel A., Zhang, Yanming, Aypar, Umut, Rao, Pavitra, Chavan, Shweta S., Haddadin, Michael, Tamari, Roni, Giralt, Sergio, Tallman, Martin S., Rampal, Raajit K., Baez, Priscilla, Kappagantula, Rajya, Kosuri, Satyajit, Dogan, Ahmet, Tickoo, Satish K., Reuter, Victor E., Bosl, George J., Iacobuzio-Donahue, Christine A., Solit, David B., Taylor, Barry S., Feldman, Darren R., and Abdel-Wahab, Omar

Subjects
Genotypes -- Identification and classification -- Health aspects, Germinoma -- Genetic aspects -- Development and progression -- Care and treatment, Gene mutation -- Health aspects, Gene expression -- Health aspects, Health care industry
Abstract

Germ cell tumors (GCTs) are the most common cancer in men between the ages of 15 and 40. Although most patients are cured, those with disease arising in the mediastinum have distinctly poor outcomes. One in every 17 patients with primary mediastinal nonseminomatous GCTs develop an incurable hematologic malignancy and prior data intriguingly suggest a clonal relationship exists between hematologic malignancies and GCTs in these cases. To date, however, the precise clonal relationship between GCTs and the diverse additional somatic malignancies arising in such individuals have not been determined. Here, we traced the clonal evolution and characterized the genetic features of each neoplasm from a cohort of 15 patients with GCTs and associated hematologic malignancies. We discovered that GCTs and hematologic malignancies developing in such individuals evolved from a common shared precursor, nearly all of which harbored allelically imbalanced p53 and/or RAS pathway mutations. Hematologic malignancies arising in this setting genetically resembled mediastinal GCTs rather than de novo myeloid neoplasms. Our findings argue that this scenario represents a unique clinical syndrome, distinct from de novo GCTs or hematologic malignancies, initiated by an ancestral precursor that gives rise to the parallel evolution of GCTs and blood cancers in these patients., Introduction Germ cell tumors (GCTs) are a model of curable cancer, as most patients with metastatic GCTs are successfully treated with cisplatin-based chemotherapy (1). However, up to 30% of patients [...]

Published
2020
Full Text
View/download PDF

91. A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial

Author

Bashir, Qaiser, Nishihori, Taiga, Pasquini, Marcelo C., Martens, Michael J., Wu, Juan, Alsina, Melissa, Anasetti, Claudio, Brunstein, Claudio, Dawson, Peter, Efebera, Yvonne, Gasparetto, Cristina, Geller, Nancy, Giralt, Sergio, Hall, Aric C., Koreth, John, McCarthy, Philip, Scott, Emma, Stadtmauer, Edward A., Vesole, David H., and Hari, Parameswaran

Published
2023
Full Text
View/download PDF

93. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Author

Roeker, Lindsey E., Dreger, Peter, Brown, Jennifer R., Lahoud, Oscar B., Eyre, Toby A., Brander, Danielle M., Skarbnik, Alan, Coombs, Catherine C., Kim, Haesook T., Davids, Matthew, Manchini, Steven T., George, Gemlyn, Shah, Nirav, Voorhees, Timothy J., Orchard, Kim H., Walter, Harriet S., Arumainathan, Arvind K., Sitlinger, Andrea, Park, Jae H., Geyer, Mark B., Zelenetz, Andrew D., Sauter, Craig S., Giralt, Sergio A., Perales, Miguel-Angel, and Mato, Anthony R.

Published
2020
Full Text
View/download PDF

94. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

Author

Jain, Tania, Knezevic, Andrea, Pennisi, Martina, Chen, Yunxin, Ruiz, Josel D., Purdon, Terence J., Devlin, Sean M., Smith, Melody, Shah, Gunjan L., Halton, Elizabeth, Diamonte, Claudia, Scordo, Michael, Sauter, Craig S., Mead, Elena, Santomasso, Bianca D., Palomba, M. Lia, Batlevi, Connie W., Maloy, Molly A., Giralt, Sergio, Smith, Eric, Brentjens, Renier, Park, Jae H., Perales, Miguel-Angel, and Mailankody, Sham

Published
2020
Full Text
View/download PDF

95. Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma

Author

Bal, Susan, Landau, Heather J., Shah, Gunjan L., Scordo, Michael, Dahi, Parastoo, Lahoud, Oscar B., Hassoun, Hani, Hultcrantz, Malin, Korde, Neha, Lendvai, Nikoletta, Lesokhin, Alexander M., Mailankody, Sham, Shah, Urvi A., Smith, Eric, Devlin, Sean M., Avecilla, Scott, Dogan, Ahmet, Roshal, Mikhail, Landgren, Ola, Giralt, Sergio A., and Chung, David J.

Published
2020
Full Text
View/download PDF

97. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Author

Montesinos, Pau, Roboz, Gail J., Bulabois, Claude-Eric, Subklewe, Marion, Platzbecker, Uwe, Ofran, Yishai, Papayannidis, Cristina, Wierzbowska, Agnieszka, Shin, Ho Jin, Doronin, Vadim, Deneberg, Stefan, Yeh, Su-Peng, Ozcan, Mehmet Ali, Knapper, Steven, Cortes, Jorge, Pollyea, Daniel A., Ossenkoppele, Gert, Giralt, Sergio, Döhner, Hartmut, Heuser, Michael, Xiu, Liang, Singh, Indrajeet, Huang, Fei, Larsen, Julie S., and Wei, Andrew H.

Published
2021
Full Text
View/download PDF

98. Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation

Author

Lin, Richard J., Baser, Raymond E., Elko, Theresa A., Korc-Grodzicki, Beatriz, Shahrokni, Armin, Maloy, Molly A., Young, James W., Tamari, Roni, Shah, Gunjan L., Shaffer, Brian C., Scordo, Michael, Sauter, Craig S., Ponce, Doris M., Politikos, Ioannis, Perales, Miguel-Angel, Papadopoulos, Esperanza B., Gyurkocza, Boglarka, Dahi, Parastoo B., Cho, Christina, Barker, Juliet N., Tomas, Ana Alarcón, Flores, Nerea Castillo, Sanchez-Escamilla, Míriam, Segundo, Lucrecia Yáñez San, Jakubowski, Ann A., and Giralt, Sergio A.

Published
2021
Full Text
View/download PDF

99. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Author

Costa, Luciano J., Derman, Benjamin A., Bal, Susan, Sidana, Surbhi, Chhabra, Saurabh, Silbermann, Rebecca, Ye, Jing C., Cook, Gordon, Cornell, Robert F., Holstein, Sarah A., Shi, Qian, Omel, James, Callander, Natalie S., Chng, Wee Joo, Hungria, Vania, Maiolino, Angelo, Stadtmauer, Edward, Giralt, Sergio, Pasquini, Marcelo, Jakubowiak, Andrzej J., Morgan, Gareth J., Krishnan, Amrita, Jackson, Graham H., Mohty, Mohamad, Mateos, Maria Victoria, Dimopoulos, Meletious A., Facon, Thierry, Spencer, Andrew, Miguel, Jesus San, Hari, Parameswaran, Usmani, Saad Z., Manier, Salomon, McCarthy, Phillip, Kumar, Shaji, Gay, Francesca, and Paiva, Bruno

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results